MRKR übertreffen die 18 der letzten 26Schätzungen.
69%
Nächster Bericht
Datum des nächsten Berichts
30. März 2026
Estimate forQ4 25(Revenue/ EPS)
$695.64K
/
-$0.20
Implizierte Änderung vonQ3 25(Revenue/ EPS)
-43.58%
/
+66.67%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
-69.11%
/
-52.38%
Marker Therapeutics, Inc. Common Stock earnings per share and revenue
On 13. Nov. 2025, MRKR reported earnings of -0.12 USD per share (EPS) for Q3 25, beating the estimate of -0.45 USD, resulting in a 73.86% surprise. Revenue reached 1.23 million, compared to an expected 737.46 tausend, with a 67.20% difference. The market reacted with a +3.48% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 695.64 tausend USD, implying an increase of 66.67% EPS, and decrease of -43.58% in Revenue from the last quarter.
FAQ
What were Marker Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Marker Therapeutics, Inc. Common Stock reported EPS of -$0.12, beating estimates by 73.86%, and revenue of $1.23M, 67.2% above expectations.
How did the market react to Marker Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.48%, changed from $0.89 before the earnings release to $0.92 the day after.
When is Marker Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 30. März 2026.
What are the forecasts for Marker Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Marker Therapeutics, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of $695.64K for Q4 2025.